Switch theme
Sign up to access all valuation multiples
Medmix AG delivers technologies in high-precision delivery devices and fluid mixing for applications. It is into two business areas Healthcare and Consumer & Industrial. The Healthcare business area is divided into the Dental, Drug Delivery, and Surgery segments. The Consumer & Industrial business area operates through the Industry and Beauty segments. The majority of its revenue is from the Consumer & Industrial segment. In the Industry segment, dispensers, cartridges, and mixers are used in the construction, transportation (automotive, railways, and aerospace), electronics assembly, infrastructure, and DIY industries. Geographically, it operates in Europe the Middle East and Africa, the Americas, and Asia-Pacific.
2021
2.7K+
LTM Revenue $583M
LTM EBITDA $102M
$789M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medmix has a last 12-month revenue (LTM) of $583M and a last 12-month EBITDA of $102M.
In the most recent fiscal year, Medmix achieved revenue of $581M and an EBITDA of $80.8M.
Medmix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medmix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $583M | XXX | $581M | XXX | XXX | XXX |
| Gross Profit | $194M | XXX | $192M | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $102M | XXX | $80.8M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $22.2M | XXX | $21.7M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $0.2M | XXX | -$8.9M | XXX | XXX | XXX |
| Net Margin | 0% | XXX | -2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $195M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medmix's stock price is CHF 11 (or $13).
Medmix has current market cap of CHF 430M (or $516M), and EV of CHF 657M (or $789M).
See Medmix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $789M | $516M | XXX | XXX | XXX | XXX | $0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medmix has market cap of $516M and EV of $789M.
Medmix's trades at 1.4x EV/Revenue multiple, and 9.8x EV/EBITDA.
Equity research analysts estimate Medmix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medmix has a P/E ratio of 2382.8x.
See valuation multiples for Medmix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $516M | XXX | $516M | XXX | XXX | XXX |
| EV (current) | $789M | XXX | $789M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 7.7x | XXX | 9.8x | XXX | XXX | XXX |
| EV/EBIT | 35.5x | XXX | 36.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 2382.8x | XXX | -58.1x | XXX | XXX | XXX |
| EV/FCF | 31.4x | XXX | 17.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedmix's last 12 month revenue growth is 2%
Medmix's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Medmix's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medmix's rule of X is 23% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medmix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medmix acquired XXX companies to date.
Last acquisition by Medmix was XXXXXXXX, XXXXX XXXXX XXXXXX . Medmix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medmix founded? | Medmix was founded in 2021. |
| Where is Medmix headquartered? | Medmix is headquartered in Switzerland. |
| How many employees does Medmix have? | As of today, Medmix has 2.7K+ employees. |
| Is Medmix publicy listed? | Yes, Medmix is a public company listed on SWX. |
| What is the stock symbol of Medmix? | Medmix trades under MEDX ticker. |
| When did Medmix go public? | Medmix went public in 2021. |
| Who are competitors of Medmix? | Similar companies to Medmix include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Medmix? | Medmix's current market cap is $516M |
| What is the current revenue of Medmix? | Medmix's last 12 months revenue is $583M. |
| What is the current revenue growth of Medmix? | Medmix revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Medmix? | Current revenue multiple of Medmix is 1.4x. |
| Is Medmix profitable? | Yes, Medmix is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medmix? | Medmix's last 12 months EBITDA is $102M. |
| What is Medmix's EBITDA margin? | Medmix's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Medmix? | Current EBITDA multiple of Medmix is 7.7x. |
| What is the current FCF of Medmix? | Medmix's last 12 months FCF is $25.1M. |
| What is Medmix's FCF margin? | Medmix's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Medmix? | Current FCF multiple of Medmix is 31.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
